Assembly biosciences, inc. (ASMB)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Cash flows from operating activities
Net loss

0

-

0

0

0

-

0

0

-45,127

-

-51,347

-50,649

-47,203

-44,261

-40,463

-35,506

-32,297

-28,453

-26,934

-31,337

-26,863

-23,788

-23,606

-17,467

-19,750

-19,403

-17,147

-17,621

-20,339

-24,790

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

474

494

547

591

610

643

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based payments to consultants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

69

130

339

0

0

0

Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

149

125

93

80

72

71

69

64

55

39

23

10

5

5

6

6

5

5

4

4

0

0

0

Stock-based compensation

18,905

20,558

20,856

21,458

30,979

28,485

24,445

21,037

11,459

8,601

6,823

5,281

4,788

5,024

5,554

5,648

6,750

7,876

8,990

15,276

12,968

10,637

8,263

1,300

1,699

1,712

2,041

2,270

2,385

2,831

0

0

0

Net accretion and amortization of investments in marketable securities

1,278

1,735

1,964

1,370

821

229

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash rent expense

4,514

4,454

3,344

2,208

1,091

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Realized loss from marketable securities

-

-

-

-

-

-

-

-

-

-

-

-1,273

-1,075

-1,140

-646

-371

-228

-27

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred income tax benefit

-793

-800

1,130

1,116

1,093

1,100

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on disposal of fixed assets

0

-102

-102

-102

-102

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other

4

5

5

155

24

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of deferred financing costs and debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Non-cash research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Expenses paid on behalf of the Company satisfied through the issuance of notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Changes in operating assets and liabilities:
Accounts receivable from collaboration

68

944

354

777

723

156

1,188

1,011

2,263

2,273

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

332

3,685

2,412

4,328

2,746

1,094

2,390

1,752

504

286

342

421

533

-93

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

0

-1,664

720

1,353

1,321

3,008

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-27

253

35

4

23

20

-34

-2

0

0

0

Accounts payable

-323

-1,962

-278

875

54

1,569

2,116

1,851

425

-244

-2,967

-1,726

-379

1,004

2,373

1,109

1,135

456

556

-891

-1,019

-2,481

0

0

0

-

-

-

-

-

-

-

-

Accrued clinical expenses

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other accrued expenses

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses

-

-

-

-

-

-

0

0

634

-

2,708

3,674

2,770

2,714

2,433

1,672

441

1,968

1,145

887

751

23

0

0

0

-

-

-

-

-

-

-

-

Deferred revenue

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

0

-4,831

-

46,810

48,070

49,315

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Security deposits

-

-

-

-

-

-

-

-

-

-

0

0

-37

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-363

-806

-1,876

232

0

0

0

Net cash used in operating activities

-85,346

-84,067

-80,266

-78,355

-73,397

-64,958

-58,001

-52,274

-48,584

1,860

590

3,683

9,273

-34,882

-29,297

-26,619

-24,234

-18,697

-16,835

-15,524

-13,461

-14,973

-16,773

-17,552

-18,611

-17,796

-15,474

-16,103

-19,660

-21,379

0

0

0

Cash flows from investing activities
Purchases of property and equipment

131

1,554

1,750

1,787

1,789

340

490

957

904

865

615

144

144

147

45

12

29

58

177

195

178

149

21

3

9

6

0

0

0

-

-

-

-

Purchases of marketable securities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of marketable securities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

-

-

-

-

-

-

-

0

61,266

-

40,022

32,590

-0

7,951

14,063

28,951

77,732

69,781

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

-

-

-

-

-

-

-

0

38,770

-

42,335

47,261

40,500

44,294

30,799

22,149

15,435

4,983

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of marketable securities

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-41,060

-50,318

-17,455

-98,874

-122,862

-135,397

-74,911

-2,821

-23,400

-15,642

1,698

14,525

40,356

36,196

16,690

-6,814

-62,326

-64,855

-61,228

-48,548

249

277

487

-3

-9

-6

0

0

0

-

-

-

-

Cash flows from financing activities
Proceeds from the exercise of stock options

-

-

-

-

-

-

-

-

-

-

1,163

901

793

153

0

257

387

554

554

296

167

0

0

0

0

-

-

-

-

-

-

-

-

Proceeds from the exercise of stock options

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from the issuance of common stock through equity plans

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

81,014

95,977

95,977

85,462

16,725

1,995

5,383

5,383

24,374

24,142

20,754

24,920

4,166

0

0

0

Proceeds from notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Proceeds from notes payable to related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Payment for deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-57

0

0

0

0

Repayment of notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Repayment of notes payable - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Proceeds from the exercise of warrants and options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

491

730

0

0

0

Net cash provided by financing activities

139,625

139,646

2,836

157,295

158,439

159,793

225,417

69,835

68,093

67,240

1,163

901

793

153

0

257

10,902

81,569

96,532

96,274

85,629

16,725

1,995

5,383

5,383

24,374

24,142

20,754

25,470

4,896

0

0

0

Net decrease in cash and cash equivalents

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-3,890

-

3,452

19,110

50,422

1,467

-12,607

-33,176

-75,659

-1,983

18,468

32,201

72,417

2,029

-14,290

-12,173

-13,236

6,572

8,662

4,646

5,806

-16,486

0

0

0

Change in unrealized (loss) gain on marketable securities available-for-sale

-

-

-

-

-

-

-

-

-

-

-

-

362

-

-448

-705

-749

-821

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of preferred stock to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

Supplemental non-cash investing and financing activities
Operating lease liabilities arising from obtaining ROU assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued offering cost related to the issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

Warrants issued to placement agent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Warrants issued to investors in connection with convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Notes and accrued interest converted to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Supplemental disclosure - cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0